CL2011000947A1 - Polipeptido lectina; molecula de acido nucleico que la codifica; vector y celula hospedera; metodo para preparar el polipeptido; composicion farmaceutica que comprende el polipeptido; uso del polipeptido para preparar un medicamento para tratar transtorno autoinmune, inflamatorio o de piel dañada de un animal. - Google Patents

Polipeptido lectina; molecula de acido nucleico que la codifica; vector y celula hospedera; metodo para preparar el polipeptido; composicion farmaceutica que comprende el polipeptido; uso del polipeptido para preparar un medicamento para tratar transtorno autoinmune, inflamatorio o de piel dañada de un animal.

Info

Publication number
CL2011000947A1
CL2011000947A1 CL2011000947A CL2011000947A CL2011000947A1 CL 2011000947 A1 CL2011000947 A1 CL 2011000947A1 CL 2011000947 A CL2011000947 A CL 2011000947A CL 2011000947 A CL2011000947 A CL 2011000947A CL 2011000947 A1 CL2011000947 A1 CL 2011000947A1
Authority
CL
Chile
Prior art keywords
polypeptide
nucleic acid
vector
medicament
animal
Prior art date
Application number
CL2011000947A
Other languages
English (en)
Inventor
Bernt Th Walther
Mirushe Miftari
Original Assignee
Leukolect As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leukolect As filed Critical Leukolect As
Publication of CL2011000947A1 publication Critical patent/CL2011000947A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1706—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Abstract

La invención se relaciona con un polipéptido lectina, con un 95% de identidad con las secuencias N° 1 - 8 o una porción de tales secuencias, donde dicha porción comprende al menos 200 aminoácidos y es al menos 95% idéntica para una región comparable con las secuencias N° 1, 2 o 5 - 8. Los polipéptidos son de la familia de leucolectinas de huevos de salmón. Así mismo, el invento se relaciona con el ácido nucleico que codifica el polipéptido, un vector y célula hospedera no nativa que comprende el polipéptido o el ácido nucleico, un método para preparar el vector o polipéptido. Además, el invento abarca una composición que comprende el polipéptido o el ácido nucleico que codifica al polipéptido. El uso dado para este polipéptido es para preparar un medicamento para tratar o prevenir un trastorno autoinmunitario de la piel, un trastorno inflamatorio de la piel o membrana mucosa o piel dañada en un animal.
CL2011000947A 2008-10-29 2011-04-28 Polipeptido lectina; molecula de acido nucleico que la codifica; vector y celula hospedera; metodo para preparar el polipeptido; composicion farmaceutica que comprende el polipeptido; uso del polipeptido para preparar un medicamento para tratar transtorno autoinmune, inflamatorio o de piel dañada de un animal. CL2011000947A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0819883.0A GB0819883D0 (en) 2008-10-29 2008-10-29 Product and uses

Publications (1)

Publication Number Publication Date
CL2011000947A1 true CL2011000947A1 (es) 2011-08-05

Family

ID=40134057

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000947A CL2011000947A1 (es) 2008-10-29 2011-04-28 Polipeptido lectina; molecula de acido nucleico que la codifica; vector y celula hospedera; metodo para preparar el polipeptido; composicion farmaceutica que comprende el polipeptido; uso del polipeptido para preparar un medicamento para tratar transtorno autoinmune, inflamatorio o de piel dañada de un animal.

Country Status (20)

Country Link
US (2) US9260498B2 (es)
EP (1) EP2358745B1 (es)
JP (1) JP5539372B2 (es)
KR (1) KR101448573B1 (es)
CN (1) CN102203127B (es)
AU (1) AU2009309477B2 (es)
BR (1) BRPI0920101B1 (es)
CA (1) CA2741823C (es)
CL (1) CL2011000947A1 (es)
CY (1) CY1119930T1 (es)
DK (1) DK2358745T3 (es)
ES (1) ES2658966T3 (es)
GB (1) GB0819883D0 (es)
MX (1) MX2011004483A (es)
NO (1) NO2358745T3 (es)
NZ (1) NZ592911A (es)
PT (1) PT2358745T (es)
RU (1) RU2528860C2 (es)
WO (1) WO2010049688A1 (es)
ZA (1) ZA201103456B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201007202D0 (en) * 2010-04-29 2010-06-16 Walther Bernt T Product and uses
GB201110783D0 (en) * 2011-06-24 2011-08-10 Aqua Bio Technology Asa Methods and uses
GB201110777D0 (en) * 2011-06-24 2011-08-10 Aqua Bio Technology Asa Methods and uses
EA201491325A1 (ru) * 2012-01-23 2015-05-29 Ресторси, Ллс Косметическое средство
CN105025906B (zh) * 2012-12-21 2020-08-25 阿克生物科技公司 来自鱼孵化液的化妆品组合物
GB201223330D0 (en) 2012-12-21 2013-02-06 Aqua Bio Technology Asa Products, methods and uses
CA2933367A1 (en) 2013-12-13 2015-06-18 Restorsea, Llc Exfoliative hair retention-promoting formulation
RU2016148865A (ru) 2014-05-16 2018-06-19 РИСТОРСИ, ЭлЭлСи Двухфазное косметическое средство
RU2658781C1 (ru) * 2017-12-28 2018-06-22 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Пептид, обладающий противоопухолевой активностью
US20210395333A1 (en) * 2018-06-07 2021-12-23 Palleon Pharmaceuticals Inc. Multimeric proteins for detecting a carbohydrate and/or treating a siglec-mediated disorder
CA3144777A1 (en) * 2019-06-28 2020-12-30 Biome Solutions Inc. Compositions, methods, and applications of a synthetic surfactant

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9219905D0 (en) 1992-09-19 1992-11-04 Univ Liverpool Lectins
WO1994011497A1 (en) * 1992-11-16 1994-05-26 Incyte Pharmaceuticals, Inc. Method of causing selective immunosuppression using hl-60-related lectins
NO314594B1 (no) * 1997-12-11 2003-04-14 Aqua Bio Technology As Ikke-selvdegraderende endoprotease, fremgangsmåte for fremstilling samt anvendelser av denne
EP1080186A2 (en) 1998-05-27 2001-03-07 Lauras AS Method for altering the activity of proteins of the pka signaling pathway
EP2177620B1 (en) 2003-03-05 2014-11-19 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US7510850B2 (en) 2005-11-10 2009-03-31 Carnegie Institution Of Washington Isolation of the mitotic spindle matrix and its methods of use
KR20070079596A (ko) * 2007-05-10 2007-08-07 김선일 피부질환 치료 보조 기능성 화장료 조성물
GB201007202D0 (en) * 2010-04-29 2010-06-16 Walther Bernt T Product and uses
GB201110783D0 (en) * 2011-06-24 2011-08-10 Aqua Bio Technology Asa Methods and uses
GB201110777D0 (en) * 2011-06-24 2011-08-10 Aqua Bio Technology Asa Methods and uses
CN105025906B (zh) * 2012-12-21 2020-08-25 阿克生物科技公司 来自鱼孵化液的化妆品组合物
GB201223330D0 (en) * 2012-12-21 2013-02-06 Aqua Bio Technology Asa Products, methods and uses

Also Published As

Publication number Publication date
AU2009309477B2 (en) 2014-12-18
US20160151454A1 (en) 2016-06-02
RU2011121616A (ru) 2012-12-10
RU2528860C2 (ru) 2014-09-20
MX2011004483A (es) 2011-09-21
US10124034B2 (en) 2018-11-13
EP2358745B1 (en) 2017-11-29
NO2358745T3 (es) 2018-04-28
ZA201103456B (en) 2012-08-29
CY1119930T1 (el) 2018-12-12
US20110280882A1 (en) 2011-11-17
JP2012506714A (ja) 2012-03-22
BRPI0920101B1 (pt) 2021-11-23
WO2010049688A1 (en) 2010-05-06
PT2358745T (pt) 2018-02-28
CA2741823A1 (en) 2010-05-06
CA2741823C (en) 2018-11-20
CN102203127B (zh) 2019-05-28
EP2358745A1 (en) 2011-08-24
KR101448573B1 (ko) 2014-10-10
KR20110095274A (ko) 2011-08-24
CN102203127A (zh) 2011-09-28
US9260498B2 (en) 2016-02-16
DK2358745T3 (en) 2018-03-05
JP5539372B2 (ja) 2014-07-02
BRPI0920101A2 (pt) 2016-08-09
AU2009309477A1 (en) 2010-05-06
ES2658966T3 (es) 2018-03-13
GB0819883D0 (en) 2008-12-03
NZ592911A (en) 2013-02-22

Similar Documents

Publication Publication Date Title
CL2011000947A1 (es) Polipeptido lectina; molecula de acido nucleico que la codifica; vector y celula hospedera; metodo para preparar el polipeptido; composicion farmaceutica que comprende el polipeptido; uso del polipeptido para preparar un medicamento para tratar transtorno autoinmune, inflamatorio o de piel dañada de un animal.
ES2619322T3 (es) Agente inductor de inmunidad
AR110502A1 (es) Polinucleótidos y polipéptidos de adenovirus
CL2013003634A1 (es) Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso
ES2662801T3 (es) Vacunas atenuadas contra Streptoccocus suis y procedimientos de fabricación y uso de las mismas
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
PE20170771A1 (es) Composiciones y metodos de uso para tratar trastornos metabolicos
ECSP15042898A (es) Péptidos y composiciones para el tratamiento de daño articular
BR112012029588A2 (pt) materiais biológicas relacionados a her3.
CO7051009A2 (es) Composiciones del factor viii y métodos para hacerlas y usarlas
CL2011003003A1 (es) Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.
CL2012001380A1 (es) Composición farmacéutica o cosmética que comprende el polipéptido coriolisina l, las proteínas muy ácidas vapi, vapii, vapiii, y una o más moléculas de ácido nucleico que codifican cualquiera de los polipéptidos recién mencionados; ácido nucleico; vector, célula hospedera; método de preparación de dichos polipéptidos; y método cosmético para exfoliar y/o humectar la piel de un animal.
CO7010783A2 (es) Proteína naglu humana recombinante y usos de la misma
JP2015511948A5 (es)
CL2013000475A1 (es) Polipeptidos de relaxina que comprende uno o mas aminoacidos codificados no naturales; acido nucleico aislado; metodo para preparar el polipeptido de relaxina.
AR093626A1 (es) Proteinas de fusion de enzima lisosomal y usos de las mismas
BR112015004701A2 (pt) polipeptídeo isolado, polipeptídeo variante, composição, uso de um polipeptídeo isolado, polinucleotídeo isolado, construção de ácido nucleico ou vetor de expressão, célula hospedeira de expressão recombinante, métodos para produção de um polipeptídeo, para melhorar o valor nutricional de uma ração animal, e para tratamento de proteínas, planta, parte de planta ou célula de planta transgênica, composição de ração animal, aditivo de ração animal, e, ração animal
BR112014023792A2 (pt) proteínas nutritivas carregadas e métodos
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
AR102445A1 (es) COMPOSICIONES Y MÉTODOS RELACIONADOS CON b-GLUCOSIDASA
EA201590611A1 (ru) Новые молекулы, связывающие il-17a, и их медицинское применение
CL2019003407A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
PE20170955A1 (es) Nuevas proteinas inhibidoras de insectos
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
AR102410A1 (es) Polipéptidos que tienen actividad xilanasa con una tasa de conversión alta de polisacáridos que contienen xilosa